Warmest Congratulations on the approval of Daoqun's self-developed Pravastatin Sodium Tablets (20mg & 10mg) by the National Medical Products Administration for market launch!

Stabilizing Conditions and Fortifying Defenses

As our fourth self-developed drug to pass evaluation, Pravastatin Sodium Tablets can help patients regulate blood lipids, stabilize their conditions, and firmly establish a strong defense for the heart and blood vessels, allowing patients to regain confidence and vitality in life.

Broad Market and Ready to Launch

Note: Data sourced from Miniwang

Globally, the prevalence of hyperlipidemia is on the rise. In China, the incidence of hyperlipidemia is also significant. According to the "Chinese Adult Dyslipidemia Prevention and Treatment Guidelines (2016 Revised Edition)," the overall prevalence of dyslipidemia in Chinese adults is as high as 40.40%, with hyperlipidemia being the main manifestation of dyslipidemia, and its prevalence is closely related.

According to the Zhongkang Kaisi system, in 2023, the total sales of lipid-lowering drugs in domestic grade hospitals and retail markets reached 25.3 billion yuan. Of this, the sales in domestic grade hospitals were approximately 14.5 billion yuan, representing a year-on-year increase of 7.1%.

Relevant data indicates that the sales scale of Pravastatin Sodium Tablets in China's three major terminal and six major markets exceeded one billion yuan in 2023, making it one of the important products in lipid-regulating chemical drugs.

Effective Lipid Reduction and Enjoying Life

Pravastatin Sodium Tablets, as an important class of statin lipid-regulating drugs, have a unique and crucial mechanism of action. It is a hydrophilic statin that selectively acts on the main organs for cholesterol synthesis—the liver and small intestine. By reversibly inhibiting the activity of HMG-CoA reductase, it moderately reduces the amount of cholesterol within cells, leading to an increase in the number of low-density lipoprotein (LDL) receptors on the cell surface, enhancing the receptor-mediated catabolism of low-density lipoprotein cholesterol (LDL-C) and the clearance of LDL-C from the bloodstream.

Additionally, it inhibits the synthesis of the precursor of LDL-C—very low-density lipoprotein cholesterol (VLDL-C) in the liver, effectively suppressing the production of LDL-C. This dual mechanism of action gives Pravastatin Sodium Tablets significant effects in reducing serum cholesterol levels and improving serum lipid profiles.

Continued Investment and Committed Innovation

Nanjing Daoqun Pharmaceutical Research and Development Co., Ltd., with its rigorous R&D attitude and advanced production technology, has invested substantial human, material, and financial resources. It has strictly followed the requirements of the National Medical Products Administration to conduct in-depth research and verification of the quality and efficacy of Pravastatin Sodium Tablets. After relentless efforts, the company has successfully obtained the drug registration certificate, which is equivalent to passing the consistency evaluation. This achievement not only adds new momentum to Daoqun's development but also sets a good example for China's pharmaceutical industry.

Collaboration Opportunities Available, Please Contact: 025-8563 7330.

About Daoqun Group

Established in 2008, Daoqun Group is based in East China with business covering pharmaceutical research and development, pharmaceutical and medical device sales, and internet + big health in three major areas. The group's business covers more than 20 provinces including Jiangsu, Zhejiang, and Shanghai, with over 3000 medical institutions and more than 35,000 healthcare professionals in long-term and stable academic cooperation, providing health services to more than 3 million patients.

Daoqun has always adhered to the corporate mission of "Supporting Healthcare and Guarding Health," launching multiple self-developed drugs by combining innovation with experience. The company will actively deepen cooperation with industry partners in the future, strive to promote the development of high-quality domestic drugs, and make more contributions to the development of the healthcare industry.

-END-